Business
Kalytera Therapeutics, Inc. Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes
Kalytera Therapeutics, Inc. Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n \n Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the \"Company\" \n or \"Kalytera\") is pleased to announce that Robert Farrell, \n J.D., has been appointed as the Company's Chief Executive Officer (\"CEO\"). \n Mr. Farrell previously held the position of Interim CEO.\n \n \n Mr. Farrell has more than 25 years of experience in the pharmaceutical, \n biotechnology and medical device sectors. Prior to joining Kalytera, Mr. \n Farrell worked as an executive officer with the Institute for One World \n Health, an affiliate of the Bill and Melinda Gates Foundation. Mr. \n Farrell has held senior positions with publicly listed companies in the \n pharmaceutical and biotechnology industries, including Titan \n Pharmaceuticals, where he served as President and CEO from 2008 to 2010, \n and as Chief Financial Officer from 1996 to 2008. Mr. Farrell received a \n law degree (J.D.) from the University of California, and his \n undergraduate degree (B.A.) from the University of Notre Dame.\n \n \n Changes to the Company's Board and Management Team\n \n \n Mr. Pini Ben-Elazar, who served as a member of the Company's Board of \n Directors since March 2017, has submitted his resignation from the Board \n of Directors, and the Company has accepted the resignation of Mr. David \n Bassa, who served as the Company's Chief Operating Officer.\n \n \n “I would like to thank Mr. Ben-Elazar and Mr. Bassa for their \n contributions to Kalytera, including their guidance and advice regarding \n the Company's GVHD program,” said Mr. Farrell. \"We are now on track to \n advance our GVHD Program into a Phase 2 study that we anticipate can be \n completed in approximately eight months, at which time we will be \n positioned to initiate the pivotal Phase 3 study required for FDA \n approval.”\n \n \n About Kalytera Therapeutics\n \n \n Kalytera Therapeutics, Inc. (\"Kalytera\") is pioneering the \n development of a next generation of cannabinoid therapeutics. Through \n its proven leadership, drug development expertise, and intellectual \n property portfolio, Kalytera seeks to establish a leading position in \n the development of novel cannabinoid medicines for a range of important \n unmet medical needs. Kalytera is focused first on developing a new class \n of proprietary cannabidiol (\"CBD\") therapeutics. CBD is a \n ...